vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and Mistras Group, Inc. (MG). Click either name above to swap in a different company.
Mistras Group, Inc. is the larger business by last-quarter revenue ($181.5M vs $168.4M, roughly 1.1× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 5.1%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs -0.8%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Mistras Group, Inc. is a global provider of asset integrity and protection solutions, offering non-destructive testing, inspection, real-time monitoring, and engineering consulting services. Its key client segments include oil and gas, aerospace, power generation, and manufacturing industries, with operations spanning North America, Europe, and Asia-Pacific, helping clients enhance operational safety, extend asset lifespans, and minimize unplanned downtime.
ESPR vs MG — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $181.5M |
| Net Profit | — | $3.8M |
| Gross Margin | — | 28.4% |
| Operating Margin | 50.6% | 7.0% |
| Net Margin | — | 2.1% |
| Revenue YoY | 143.7% | 5.1% |
| Net Profit YoY | — | -27.4% |
| EPS (diluted) | $0.32 | $0.12 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $181.5M | ||
| Q3 25 | $87.3M | $195.5M | ||
| Q2 25 | $82.4M | $185.4M | ||
| Q1 25 | $65.0M | $161.6M | ||
| Q4 24 | $69.1M | $172.7M | ||
| Q3 24 | $51.6M | $182.7M | ||
| Q2 24 | $73.8M | $189.8M | ||
| Q1 24 | $137.7M | $184.4M |
| Q4 25 | — | $3.8M | ||
| Q3 25 | $-31.3M | $13.1M | ||
| Q2 25 | $-12.7M | $3.0M | ||
| Q1 25 | $-40.5M | $-3.2M | ||
| Q4 24 | — | $5.2M | ||
| Q3 24 | $-29.5M | $6.4M | ||
| Q2 24 | $-61.9M | $6.4M | ||
| Q1 24 | $61.0M | $995.0K |
| Q4 25 | — | 28.4% | ||
| Q3 25 | — | 29.8% | ||
| Q2 25 | — | 29.1% | ||
| Q1 25 | — | 25.3% | ||
| Q4 24 | — | 26.5% | ||
| Q3 24 | — | 26.8% | ||
| Q2 24 | — | 27.1% | ||
| Q1 24 | — | 25.0% |
| Q4 25 | 50.6% | 7.0% | ||
| Q3 25 | -11.4% | 10.4% | ||
| Q2 25 | 8.6% | 4.5% | ||
| Q1 25 | -34.0% | -0.6% | ||
| Q4 24 | -6.4% | 6.1% | ||
| Q3 24 | -31.0% | 6.5% | ||
| Q2 24 | 3.5% | 6.3% | ||
| Q1 24 | 52.5% | 3.0% |
| Q4 25 | — | 2.1% | ||
| Q3 25 | -35.9% | 6.7% | ||
| Q2 25 | -15.4% | 1.6% | ||
| Q1 25 | -62.2% | -2.0% | ||
| Q4 24 | — | 3.0% | ||
| Q3 24 | -57.2% | 3.5% | ||
| Q2 24 | -83.9% | 3.4% | ||
| Q1 24 | 44.3% | 0.5% |
| Q4 25 | $0.32 | $0.12 | ||
| Q3 25 | $-0.16 | $0.41 | ||
| Q2 25 | $-0.06 | $0.10 | ||
| Q1 25 | $-0.21 | $-0.10 | ||
| Q4 24 | $-0.14 | $0.17 | ||
| Q3 24 | $-0.15 | $0.20 | ||
| Q2 24 | $-0.33 | $0.20 | ||
| Q1 24 | $0.34 | $0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $28.0M |
| Total DebtLower is stronger | — | $178.0M |
| Stockholders' EquityBook value | $-302.0M | $235.1M |
| Total Assets | $465.9M | $578.8M |
| Debt / EquityLower = less leverage | — | 0.76× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $28.0M | ||
| Q3 25 | $92.4M | $27.8M | ||
| Q2 25 | $86.1M | $20.0M | ||
| Q1 25 | $114.6M | $18.5M | ||
| Q4 24 | $144.8M | $18.3M | ||
| Q3 24 | $144.7M | $20.4M | ||
| Q2 24 | $189.3M | $17.2M | ||
| Q1 24 | $226.6M | $16.9M |
| Q4 25 | — | $178.0M | ||
| Q3 25 | — | $202.3M | ||
| Q2 25 | — | $189.4M | ||
| Q1 25 | — | $171.9M | ||
| Q4 24 | — | $169.6M | ||
| Q3 24 | — | $189.7M | ||
| Q2 24 | — | $199.7M | ||
| Q1 24 | — | $198.4M |
| Q4 25 | $-302.0M | $235.1M | ||
| Q3 25 | $-451.4M | $227.4M | ||
| Q2 25 | $-433.5M | $215.8M | ||
| Q1 25 | $-426.2M | $198.7M | ||
| Q4 24 | $-388.7M | $198.6M | ||
| Q3 24 | $-370.2M | $205.2M | ||
| Q2 24 | $-344.2M | $193.2M | ||
| Q1 24 | $-294.3M | $187.1M |
| Q4 25 | $465.9M | $578.8M | ||
| Q3 25 | $364.0M | $596.3M | ||
| Q2 25 | $347.1M | $571.0M | ||
| Q1 25 | $324.0M | $526.8M | ||
| Q4 24 | $343.8M | $523.0M | ||
| Q3 24 | $314.1M | $551.7M | ||
| Q2 24 | $352.3M | $548.1M | ||
| Q1 24 | $373.1M | $542.1M |
| Q4 25 | — | 0.76× | ||
| Q3 25 | — | 0.89× | ||
| Q2 25 | — | 0.88× | ||
| Q1 25 | — | 0.87× | ||
| Q4 24 | — | 0.85× | ||
| Q3 24 | — | 0.92× | ||
| Q2 24 | — | 1.03× | ||
| Q1 24 | — | 1.06× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $32.1M |
| Free Cash FlowOCF − Capex | — | $26.0M |
| FCF MarginFCF / Revenue | — | 14.3% |
| Capex IntensityCapex / Revenue | 0.0% | 3.4% |
| Cash ConversionOCF / Net Profit | — | 8.55× |
| TTM Free Cash FlowTrailing 4 quarters | — | $8.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $32.1M | ||
| Q3 25 | $-4.3M | $4.5M | ||
| Q2 25 | $-31.4M | $-9.3M | ||
| Q1 25 | $-22.6M | $5.6M | ||
| Q4 24 | $-35.0M | $25.7M | ||
| Q3 24 | $-35.3M | $19.4M | ||
| Q2 24 | $-7.2M | $4.5M | ||
| Q1 24 | $53.8M | $604.0K |
| Q4 25 | — | $26.0M | ||
| Q3 25 | — | $-4.1M | ||
| Q2 25 | — | $-14.7M | ||
| Q1 25 | — | $1.1M | ||
| Q4 24 | — | $22.1M | ||
| Q3 24 | $-35.5M | $14.6M | ||
| Q2 24 | $-7.3M | $-284.0K | ||
| Q1 24 | $53.8M | $-4.2M |
| Q4 25 | — | 14.3% | ||
| Q3 25 | — | -2.1% | ||
| Q2 25 | — | -7.9% | ||
| Q1 25 | — | 0.7% | ||
| Q4 24 | — | 12.8% | ||
| Q3 24 | -68.7% | 8.0% | ||
| Q2 24 | -9.9% | -0.1% | ||
| Q1 24 | 39.0% | -2.3% |
| Q4 25 | 0.0% | 3.4% | ||
| Q3 25 | 0.0% | 4.4% | ||
| Q2 25 | 0.0% | 2.9% | ||
| Q1 25 | 0.0% | 2.8% | ||
| Q4 24 | 0.0% | 2.1% | ||
| Q3 24 | 0.3% | 2.6% | ||
| Q2 24 | 0.1% | 2.5% | ||
| Q1 24 | 0.1% | 2.6% |
| Q4 25 | — | 8.55× | ||
| Q3 25 | — | 0.34× | ||
| Q2 25 | — | -3.07× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 4.96× | ||
| Q3 24 | — | 3.02× | ||
| Q2 24 | — | 0.71× | ||
| Q1 24 | 0.88× | 0.61× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
MG
Segment breakdown not available.
